

15 March 2017

Australian Securities Exchange
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

Alcidion to Present at TechKnow Invest Roadshow

Alcidion Group Limited (ASX:ALC) today announced that it will present at the TechKnow Invest Roadshow in Melbourne and Sydney in the week commencing March 20th 2017.

The TechKnow Invest Roadshow is an investor focused technology event, that introduces technology companies operating in an innovative space to investors and stockbrokers.

The roadshow will be replicated in Melbourne and Sydney and will feature a 15-minute presentation from each of the participating 17 technology companies.

Executive Director, Mr. Nathan Buzza will present on behalf of Alcidion. Updating the group on the latest developments within the company, first year as a listed company and milestone targets over the coming months.

In October 2016, the TechKnow Invest Roadshow was staged in Brisbane, Sydney & Melbourne and attracted over 700 attendees.

Event Details

Sydney Event

Date: Tuesday 21st March 2017
Alcidion presenting at 12:25 pm
Venue: Radisson Blu Hotel
27 O'Connell Street
Sydney NSW 2000

Melbourne Event

Date: Thursday 23rd March 2017
Alcidion presenting at 11:10 am
Venue: Grand Hyatt Hotel
123 Collins Street
Melbourne VIC 3000

A copy of the presentation is included as an Appendix to this announcement.

ENDS

For further information, please contact:

Nathan Buzza, Executive Director

Ph: +61 (0) 488862222

Alcidion Group Limited

nathan.buzza@alcidion.com

Ray Blight, Chief Executive Officer

Ph: +61 (08) 8208 4600

Alcidion Group Limited

ray.blight@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publically listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.



Alcidion Group Limited

Alcidion Investor Presentation

March 2017



Disclaimer

This presentation has been prepared by Alcidion Group Limited (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).


Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other Jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.



ASX Ticker

ALC

Market Capitalisation

\$42.14 million

Ownership

38% Founders

14% BlueSky Private Equity

5% Owned by Employees

Share Price

7.00c

Share Range (12 Months)

4.00c → 14.00c

Share Volume (12 Months)

148m Shares (TTM)

Cash on hand

\$5.73 million

Enterprise Value

\$42 million

Shares on Issue

603 million

Employees

30 x FTE

Revenues FY16

\$4 million

Cumulative R&D Investment

\$19 million

Contingent Share Rights

*11,827,957 Shares on achieving \$10m in TTM revenue by 29/2/2018 and;
15,053,763 Shares on achieving \$15m in TTM revenue within 29/2/2019.*

All financial data has been rounded as of 31 December 2016

Equity data accurate as of 14 March 2017

WHY IS DIGITAL HEALTH SUCH AN EXCITING INVESTMENT OPPORTUNITY ?

- The global population is aging, resulting in a dramatic and unparalleled increase in population, complex patients with multiple co-morbidities.
- The United States spends 18% of GDP on Healthcare, representing over \$USD3 trillion dollars annually, which is set to grow to 37% by 2050.
- Global expenditure on Healthcare IT in 2014 was \$USD83.98 billion and is expected to grow to \$USD114.75 billion by 2019
(Source:Health Analytics)



- The Patient Protection & Affordable Care in 2010, mandated that all US hospitals upgrade their Clinical Information Systems.
- This HITECH Act stipulates that healthcare providers must demonstrate the meaningful use of health IT by 2016 or face a reduction in Medicare reimbursements.
- Global Healthcare organisations are embracing EMRAM to improve efficiency in Healthcare.



- FDA Regulating the environment.
- The Global Governments are allocating funds to Digital Health:
 - The United States government has set aside more than \$USD20 billion in stimulus funds to implement Electronic Health Records nationwide
 - The United Kingdom has allocated £4 billion to transition the National Health Service into a paperless environment.
 - Australian Digital Health Agency formed 27th Jan 2016.
- The adoption of Digital Health encourage the adoption of Digital Health – a self fulfilling prophecy.



A man with dark hair and glasses, wearing a white lab coat, is seen from the side, looking at a tablet. The tablet screen shows a medical interface with a red header and a table of data. The background is blurred, showing what appears to be a clinical setting.

“This has skyrocketed the efficiency in patient care as well as the **safety**”

Professor Tissa Wijerante
Consulting Neurologist
Director of the Stroke & Neuroscience Unit
Western Health



“You’ll see nearly all of the clinical, executive and divisional directors walking around with the bed management views on their iPads, and the same with the bed management staff, the quality managers, the NUMs and any staff that help move the patients around.”

Jason Whakaari
Executive Director of ICT, Western Health



**Chief Medical Officer
Prof. Malcolm Pradhan**

- Formal qualifications in medicine complimented by a PhD in Medical Informatics from Stanford University.
- Founding fellow of the Australasian College of Health Informatics.
- Associate Dean of IT & Director of Medical Informatics at the University of Adelaide.
- Clinical Lead within the Australian Government's National e-Health Transition Authority.



**Non-Executive Director
Mr. Brian Leedman**

- Formal qualifications include a Bachelor of Economics and a MBA.
- Co-Founder of Resapp Health ([ASX:RAP](#)).
- Co-Founder of Oncosil Medical ([ASX:OSL](#)).
- Co-Founder of Imugene ([ASX:IMU](#)).
- WA Chairman of AusBiotech.
- Previously Marketing Manager at Ernst & Young.



**Chief Executive Officer
Mr. Ray Blight**

- Formal qualifications include a Bachelor of Technology, Bachelor of Economics and a MBA.
- Former CEO of the South Australian Health Commission and Chair of the Health Ministers' Advisory Council
- Consultant to the World Bank.
- Chairs the University of SA IT & Mathematical Sciences Advisory Board.



**Executive Director
Mr. Nathan Buzza**

- Former founder & CEO of Clinical Middleware provider, Commtech Wireless.
- EY "Entrepreneur of the Year".
- BRW in the Fast100 for three consecutive years.
- Western Australia IT & telecommunications Life Time achievement Award for contribution to the IT community.
- Previously the second largest shareholder of Azure Healthcare ([ASX:AZV](#)).



**Non-Executive Director
Mr. Nick Dignam**

- Formal qualifications include a Bachelor of Commerce, Bachelor of Law and a Masters of Applied Finance.
- Investment Director of BlueSky ([ASX:BLA](#)), a listed alternative asset manager with \$1.7b of assets under management.
- Responsible for originating new investment opportunities, working with portfolio companies to deliver growth and managing exit processes.
- Joined Blue Sky from Catalyst Investment.

- Hospitals are built upon a complex eco-system of disparate Clinical Information Systems.
- Alcidion's Miya platform integrates disparate Clinical Information Systems to identify emerging clinical risk and push this clinical intelligence to the care team via a continuum of mobile and desktop devices.
- Under the stewardship of our CMO, Professor Malcolm Pradhan and CEO Ray Blight, the former Chief Executive of the SA Health Commission, Alcidion has invested over \$19m in the development of the Miya Platform.




- The technology is already deployed and operational at:
 - Western Health (3 Hospitals).
 - Northern Territory Health Department (5 Hospitals).
 - Tasmania Health (4 Hospitals).
 - Royal Melbourne Hospital.
 - Coffs Harbour Base Hospital.
 - Sunshine Coast University Hospital.
 - NT Cardiac (about to be deployed).
- By providing clinicians with decision support tools and prompting care guidance in accordance with hospital approved clinical protocols, patient clinical outcomes may be improved.

Alcidion is intending to revolutionize the healthcare industry, by providing an agnostic Clinical Information System that resides over the top of the existing systems.








- Over 1200 Exhibitors, contributing to \$USD56b being spent in Healthcare IT with 45,000 attendees.
- Commenced preliminary discussions with potential strategic partners in the United States & Canada.
- Reviewed competitive offerings:
 - Few Competitors within the independent Patient Flow, Electronic Bed Management, Clinical Decision Support Space.
 - Monolithic Solutions are extraordinary expensive and form part of a much broader eHealth strategy.
- Trump administration demanding substantial improvements in healthcare efficiency and looking towards Information Technology Solutions to address these challenges.



- Listed Alcidion on the ASX on February 29 2016, with \$7m in cash, with minimal debt.
- Posted two consecutive cashflow positive quarters for Q1 and Q2 in FY17, with total cash of \$5.75m (plus R&D Tax Provision of \$576k)
- Commenced our commercialiation strategy, which in broad terms will see the Alcidion Sales Team systematically engage the continuum of Australian and New Zealand healthcare.
- Executed a \$2.35 MoU with Western Health, signifying the transition of our Patient Flow and Bed Management applications from Pilot Site to commercial utilization.
- Signed an agreement with Calvary Health to assist the organization with streamlining clinical coding and patient data across their facilities.
- Late stage negotiations with a District Health Board in New Zealand, with expectations to close in Q4 FY17.



- Invested \$1.5m developing a Computerized Physician Order Entry (CPOE) platform, in the form of a Best Practice Pathology Ordering product that automates the electronic ordering of pathology for ED physicians.
- Tasmania's Northern Integrated Care Service went live with Alcidion.
- Deployed our Critical Test Results Management Platform across the Northern Territory.
- Announced that our strategic partner, FUJIFILM had secured multiples sales of our intelligent Cardiovascular Information System (iCVIS).
- Integrated into the Cerner EMR Platform – Alcidion's first deployment in NSW.
- Reviewed potential acquisitions, that would compliment Alcidion Product Folio and contribute to the company's overall profitability and accelerate the commercialisation initiatives.



Unique Opportunity To Be Part of the New Digital Health Economy



AFFORDABLE CARE ACT

The introduction of the Patient Protection & Affordable Care Act requires US hospitals to adopt Electronic Medical Records or face a reduction in Medicare reimbursements.

Experienced Management Team



“Capable and Experienced Management Team with a strong track record of commercializing healthcare software, including the former CEO & Chairman of the South Australian Health Commission, a Stanford qualified Medical Doctor and a former Ernst & Young Entrepreneur of the Year.”

Proven Technology

Alcidion's platform is installed into 15 large tertiary hospitals including Footscray, Sunshine, Williamstown, Royal Darwin & Alice Springs Hospitals and throughout Tasmania.



Disruptive Technology Platform

A person wearing a white hospital gown and a wristband is lying in a hospital bed. They are holding a tablet computer with both hands. The tablet screen displays a medical dashboard with various charts, graphs, and data points. The background is slightly blurred, showing the hospital bed and some papers.

The platform is at the forefront of medical technology, on the crest of the next generation of healthcare technologies.



Strong Growth Platform

The business recently secured a \$2.35m MoU with Western Health to adopt its Patient Flow Solutions across its three locations.

The business recently secured a \$2.35m MoU with Western Health to adopt its Patient Flow Solutions across its three locations.

Fully Funded

The company is fully funded, with \$5.73m in cash and minimal debt, with two quarters of positive cashflow.

The tablet screen shows a financial spreadsheet titled "Hospital" with a subtitle "Post-Operative & Clinical Care Services". The table has columns for "Line", "Category", "Units", "Rate", "Total", "Status", and "Comments". The data is as follows:

Line	Category	Units	Rate	Total	Status	Comments
100	FTW	1	200	200	6	
101	FTW	15	8	120	7	
102	FTW	10	10	100	8	
103	FTW	10	10	100	9	
104	FTW	2	200	400	10	
105	FTW	1	200	200	11	
106	FTW	1	200	200	12	
107	FTW	1	200	200	13	
108	FTW	1	200	200	14	
109	FTW	1	200	200	15	
110	FTW	1	200	200	16	
111	FTW	1	200	200	17	
112	FTW	1	200	200	18	
113	FTW	1	200	200	19	
114	FTW	1	200	200	20	
115	FTW	1	200	200	21	
116	FTW	1	200	200	22	
117	FTW	1	200	200	23	
118	FTW	1	200	200	24	
119	FTW	1	200	200	25	
120	FTW	1	200	200	26	
121	FTW	1	200	200	27	
122	FTW	1	200	200	28	
123	FTW	1	200	200	29	
124	FTW	1	200	200	30	
125	FTW	1	200	200	31	
126	FTW	1	200	200	32	
127	FTW	1	200	200	33	
128	FTW	1	200	200	34	
129	FTW	1	200	200	35	
130	FTW	1	200	200	36	
131	FTW	1	200	200	37	
132	FTW	1	200	200	38	
133	FTW	1	200	200	39	
134	FTW	1	200	200	40	
135	FTW	1	200	200	41	
136	FTW	1	200	200	42	
137	FTW	1	200	200	43	
138	FTW	1	200	200	44	
139	FTW	1	200	200	45	
140	FTW	1	200	200	46	
141	FTW	1	200	200	47	
142	FTW	1	200	200	48	
143	FTW	1	200	200	49	
144	FTW	1	200	200	50	
145	FTW	1	200	200	51	
146	FTW	1	200	200	52	
147	FTW	1	200	200	53	
148	FTW	1	200	200	54	
149	FTW	1	200	200	55	
150	FTW	1	200	200	56	
151	FTW	1	200	200	57	
152	FTW	1	200	200	58	
153	FTW	1	200	200	59	
154	FTW	1	200	200	60	
155	FTW	1	200	200	61	
156	FTW	1	200	200	62	
157	FTW	1	200	200	63	
158	FTW	1	200	200	64	
159	FTW	1	200	200	65	
160	FTW	1	200	200	66	
161	FTW	1	200	200	67	
162	FTW	1	200	200	68	
163	FTW	1	200	200	69	
164	FTW	1	200	200	70	
165	FTW	1	200	200	71	
166	FTW	1	200	200	72	
167	FTW	1	200	200	73	
168	FTW	1	200	200	74	
169	FTW	1	200	200	75	
170	FTW	1	200	200	76	
171	FTW	1	200	200	77	
172	FTW	1	200	200	78	
173	FTW	1	200	200	79	
174	FTW	1	200	200	80	
175	FTW	1	200	200	81	
176	FTW	1	200	200	82	
177	FTW	1	200	200	83	
178	FTW	1	200	200	84	
179	FTW	1	200	200	85	
180	FTW	1	200	200	86	
181	FTW	1	200	200	87	
182	FTW	1	200	200	88	
183	FTW	1	200	200	89	
184	FTW	1	200	200	90	
185	FTW	1	200	200	91	
186	FTW	1	200	200	92	
187	FTW	1	200	200	93	
188	FTW	1	200	200	94	
189	FTW	1	200	200	95	
190	FTW	1	200	200	96	
191	FTW	1	200	200	97	
192	FTW	1	200	200	98	
193	FTW	1	200	200	99	
194	FTW	1	200	200	100	
195	FTW	1	200	200	101	
196	FTW	1	200	200	102	
197	FTW	1	200	200	103	
198	FTW	1	200	200	104	
199	FTW	1	200	200	105	
200	FTW	1	200	200	106	
201	FTW	1	200	200	107	
202	FTW	1	200	200	108	
203	FTW	1	200	200	109	
204	FTW	1	200	200	110	
205	FTW	1	200	200	111	
206	FTW	1	200	200	112	
207	FTW	1	200	200	113	
208	FTW	1	200	200	114	
209	FTW	1	200	200	115	
210	FTW	1	200	200	116	
211	FTW	1	200	200	117	
212	FTW	1	200	200	118	
213	FTW	1	200	200	119	
214	FTW	1	200	200	120	
215	FTW	1	200	200	121	
216	FTW	1	200	200	122	
217	FTW	1	200	200	123	
218	FTW	1	200	200	124	
219	FTW	1	200	200	125	
220	FTW	1	200	200	126	
221	FTW	1	200	200	127	
222	FTW	1	200	200	128	
223	FTW	1	200	200	129	
224	FTW	1	200	200	130	
225	FTW	1	200	200	131	
226	FTW	1	200	200	132	
227	FTW	1	200	200	133	
228	FTW	1	200	200	134	
229	FTW	1	200	200	135	
230	FTW	1	200	200	136	
231	FTW	1	200	200	137	
232	FTW	1	200	200	138	
233	FTW	1	200	200	139	
234	FTW	1	200	200	140	
235	FTW	1	200	200	141	
236	FTW	1	200	200	142	
237	FTW	1	200	200	143	
238	FTW	1	200	200	144	
239	FTW	1	200	200	145	
240	FTW	1	200	200	146	
241	FTW	1	200	200	147	
242	FTW	1	200	200	148	
243	FTW	1	200	200	149	
244	FTW	1	200	200	150	
245	FTW	1	200	200	151	
246	FTW	1	200	200	152	
247	FTW	1	200	200	153	
248	FTW	1	200	200	154	
249	FTW	1	200	200	155	
250	FTW	1	200	200	156	
251	FTW	1	200	200	157	
252	FTW	1	200	200	158	
253	FTW	1	200	200	159	
254	FTW	1	200	200	160	
255	FTW	1	200	200	161	
256	FTW	1	200	200	162	
257	FTW	1	200	200	163	
258	FTW	1	200	200	164	
259	FTW	1	200	200	165	
260	FTW	1	200	200	166	
261	FTW	1	200	200	167	
262	FTW	1	200	200	168	
263	FTW	1	200	200	169	
264	FTW	1	200	200	170	
265	FTW	1	200	200	171	
266	FTW	1	200	200	172	
267	FTW	1	200	200	173	
268	FTW	1	200	200	174	
269	FTW	1	200	200	175	
270	FTW	1	200	200	176	
271	FTW	1	200	200	177	
272	FTW	1	200	200	178	
273	FTW	1	200	200	179	
274	FTW	1	200	200	180	
275	FTW	1	200	200	181	
276	FTW	1	200	200	182	
277	FTW	1	200	200	183	
278	FTW	1	200	200	184	
279	FTW	1	200	200	185	
280	FTW	1	200	200	186	
281	FTW	1	200	200	187	
282	FTW	1	200	200	188	
283	FTW	1	200	200	189	
284	FTW	1	200	200	190	
285	FTW	1	200	200	191	
286	FTW	1	200	200	192	
287	FTW	1	200	200	193	
288	FTW	1	200	200	194	
289	FTW	1	200	200	195	
290	FTW	1	200	200	196	
291	FTW	1	200	200	197	
292	FTW	1	200	200	198	
293	FTW	1	200	200	199	
294	FTW	1	200	200	200	